1. Yu, J., Li, Y., Li, Y., Liu, X., Huo, Q., Wu, N., Zhang, Y., Zeng, T., Zhang, Y., Li, H. Y., Lian, J., Zhou, J., Moses, E. J., Geng, J., Lin, J., Li, W., & Zhu, X. (2025). Phosphorylation of FOXN3 by NEK6 promotes pulmonary fibrosis through Smad signaling. Nature communications, 16(1), 1865.(最后通讯)
2. Du, J., Jin, L., Wang, S., Hu, X., Yu, J., Yu, J., Huo, Q., Wu, N., Liu, X., Yang, Y., Zhang, Y., Huang, S., Zhou, J., Zheng, S. G., Zheng, C., & Zhu, X. (2026). FOXN3 integrates the KU70/KU80/SREBP- 1 complex to regulate lipid metabolism in non-alcoholic fatty liver disease. Nucleic acids research, 54(5). (最后通讯)
3. Zhu, X., Huo, Q., Jin, L., Du, J., Yu, J., Wang, H., Wu, N., Li, Y., Rui, Y., Zhao, C., Zhou, J., Zhang, Y., Li, H., Lin, J., Zheng, C., & Li, W. (2026). PARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation. Science advances, 12(1). (第一作者)
4. Zhu, X., Huang, B., Zhao, F., Lian, J., He, L., Zhang, Y., Ji, L., Zhang, J., Yan, X., Zeng, T., Ma, C., Liang, Y., Zhang, C., & Lin, J. (2023). p38-mediated FOXN3 phosphorylation modulates lung inflammation and injury through the NF-ĸB signaling pathway. Nucleic acids research, 51(5), 2195–2214. (第一作者)
5. Yu, J., Liu, X., Jin, L., Li, H., Wang, S., Yang, Y., Chen, X., Wang, H., Li, Y., Lian, J., Shi, C., Li, H., Zhang, Y., Moses, E. J., Zhang, H., Zheng, C., & Zhu, X. (2025). Extracellular vesicles derived from menstrual blood-derived mesenchymal stem cells suppress inflammatory atherosclerosis by inhibiting NF-ĸB signaling. BMC medicine, 23(1), 565.(最后通讯)
专利:
1. 朱鑫星,林俊堂,于金金,杨芬,钟根深,郭睿,杜江,动脉粥样硬化分子标志物及其应用,中国,ZL201811140906.8